ArticleJACC. Case reports2026
Unusual Cardiac Complication in Still's Disease: MAS-Induced Cardiogenic Shock.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.Current cardiology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStill's disease can precipitate macrophage activation syndrome (MAS) and, rarely, acute cardiac dysfunction. We describe MAS-associated cardiogenic shock in which myocardial stunning appeared more likely than overt myocarditis. CASE SUMMARY: A 20-year-old woman with Still's disease on anakinra and corticosteroids presented with status epilepticus after missing medications. She developed acute biventricular failure and cardiogenic shock. Infectious evaluation was negative. Troponin elevation was modest, while N-terminal pro-B-type natriuretic peptide was markedly increased (8,000 ng/L). High-dose intravenous methylprednisolone (500 mg/d for 3 days) and reinitiation of anakinra produced rapid hemodynamic stabilization and ventricular recovery. DISCUSSION: The clinical course suggests cytokine-mediated myocardial dysfunction, although myocarditis could not be fully excluded. Prompt recognition of MAS and early initiation of corticosteroids and IL-1 blockade are essential for reversibility of cardiac impairment. TAKE-HOME MESSAGES: MAS can cause reversible cardiogenic shock in Still's disease. HLA-DRB1∗15 may signal susceptibility to more severe inflammatory phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.